^
    1d
    Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) (clinicaltrials.gov)
    P2, N=20, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Mar 2028 | Trial primary completion date: Nov 2026 --> May 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IL2RA (Interleukin 2 receptor, alpha) • XIAP (X-Linked Inhibitor Of Apoptosis) • PRF1 (Perforin 1) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Jakafi (ruxolitinib) • methylprednisolone sodium succinate
    1d
    Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, OHSU Knight Cancer Institute
    New P1 trial
    |
    CD33 (CD33 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    azacitidine • Jakafi (ruxolitinib) • cyclophosphamide
    1d
    Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen (clinicaltrials.gov)
    P2, N=50, Recruiting, Chinese PLA General Hospital | Trial completion date: Jun 2023 --> Jun 2031 | Trial primary completion date: Jun 2022 --> Jun 2030
    Trial completion date • Trial primary completion date
    |
    cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Epidaza (chidamide) • carmustine
    1d
    A prospective clinical study of the combination regimen of Rabbit Anti-Human Thymocyte Immunoglobulin, Cyclosporine, Mycophenolate Mofetil, and Ruxolitinib for the prevention of graft-versus-host disease in haploidentical hematopoietic stem cell transplantation. (ChiCTR2600120679)
    P=N/A, N=40, The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university
    New trial
    |
    Jakafi (ruxolitinib) • cyclosporine
    2d
    Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease (clinicaltrials.gov)
    P2, N=14, Recruiting, University of Pennsylvania | Trial primary completion date: Dec 2028 --> Jul 2028
    Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    Jakafi (ruxolitinib) • Sylvant (siltuximab)
    2d
    Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=41, Recruiting, Washington University School of Medicine | Trial completion date: Dec 2026 --> Nov 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • Orencia (abatacept)
    2d
    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma (clinicaltrials.gov)
    P2, N=83, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib)
    3d
    Validity of The Danish National Chronic Myeloid Neoplasia Registry. (PubMed, Clin Epidemiol)
    PPV was high for core diagnostic, treatment and comorbidity variables: ET (0.91), PV (0.95) and PMF (0.97), date of diagnosis (0.97), splenomegaly (0.98), JAK2V617F (0.97), CALR (0.92), hypertension (0.93), hyperlipidemia (0.90), diabetes (0.97), and common treatments (phlebotomy, hydroxyurea, interferon, ruxolitinib ≥.93). The DMR demonstrates high validity for several clinically relevant variables and constitutes a reliable source of real-world data in MPN research and therefore, crosslinking registry variables with other data sources may enable robust epidemiological studies and unprecedented precision in real-world evidence for MPN patients. Nevertheless, variable documentation and data quality must be critically assessed to account for changes in data entry practices across time periods.
    Journal • JAK2V617F
    |
    CALR (Calreticulin)
    |
    Jakafi (ruxolitinib) • hydroxyurea
    4d
    Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. (PubMed, Blood Neoplasia)
    In conclusion, ruxolitinib was the most potent, and selective JAKinib with no relevant effects in JAK2-independent cells. In contrast, fedratinib, pacritinib, and momelotinib inhibited many other kinases and inhibited cell growth by JAK2-unrelated mechanisms at clinically relevant concentrations.
    Journal
    |
    ACVR1 (Activin A Receptor Type 1)
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    4d
    Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia. (PubMed, Blood Neoplasia)
    Our study identified cellular and molecular biomarkers, notably CD56, that predict resistance to Rux + Ven, but further work is needed to understand and validate their effect in AML. This trial was registered at www.clinicaltrials.gov as #NCT03874052.
    Clinical • P1 data • Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • ITGAM (Integrin, alpha M)
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)
    4d
    PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis. (PubMed, Am J Cancer Res)
    We identify a link between IL-6 expression and PIM1 expression and activity in human ccRCC tumors and cell lines. Our work provides evidence that targeting an IL-6/JAK/STAT/PIM1 axis may be a viable therapeutic strategy for patients with PIM1-high expressing ccRCC.
    Journal
    |
    IL6 (Interleukin 6) • PIM1 (Pim-1 Proto-Oncogene)
    |
    Jakafi (ruxolitinib)
    4d
    Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=42, Recruiting, City of Hope Medical Center | Suspended --> Recruiting | Trial completion date: Jun 2029 --> Jun 2028 | Trial primary completion date: Jun 2029 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CXCL9 (Chemokine (C-X-C motif) ligand 9) • MMP3 (Matrix metallopeptidase 3)
    |
    Jakafi (ruxolitinib)